Fractyl plans to file a De Novo request with the FDA in late Q4, yet its shares closed about 63% lower that day over a class action and doubts about 12-month results.
Recap by typeshit. Full story at Medtech Insight.
U of T researchers built the AI tool with the aim of speeding up how new peptide drugs are found. The university's announcement has the details.
Health records from 131 million adults linked GLP-1s to fewer dialysis or transplant cases. The researchers stress the study is observational and can't prove cause.
Centre Daily Times looks at how peptides taken by mouth can get past the gut intact and reach specific spots in the body, a key hurdle for pill versions of these drugs.
18:20
Dr. Lindsay Ogle, an MD who covers metabolic health, talks through options for people whose appetite hasn't settled on GLP-1 treatment.
UW Medicine notes that many of these experimental peptides have not been regulated by the FDA, and some have never been tested in people.
Dr Bajekal flags that people on Mounjaro, semaglutide or Wegovy should talk it through with their doctor ahead of an operation.
Loading…